Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

The Share

See More

Press Releases

Invitation to presentation of Sedana Medical’s interim report for the third quarter 2022

Non-regulatory

Sedana Medical AB (publ) plans to present its interim report for the third quarter 2022 in an audioc…

Sedana Medical’s products receive MDR certification

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medica…

Sedana Medical AB Interim report January-June 2022

Regulatory

Committed to change the standard of care, with commercial progress and a strong balance sheet.

View All Press Releases

Financial Calendar

Interim report Q3 2022 25 October 2022 07:00

See More